Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Skye Bioscience Inc
(OP:
SKYE
)
12.81
UNCHANGED
Last Price
Updated: 3:57 PM EDT, Apr 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Skye Bioscience Inc
< Previous
1
2
Next >
Pii Congratulates Skye Bioscience for First-in-Human Phase 1 Trial of Proprietary Cannabinoid Derivative and Nanoemulsion Formulation Designed to Potentially Treat Glaucoma.
January 24, 2023
From
Pharmaceutics International Inc.
Via
GlobeNewswire
Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
December 20, 2022
San Diego, California--(Newsfile Corp. - December 20, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Exposures
Product Safety
Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
December 16, 2022
San Diego, California--(Newsfile Corp. - December 16, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer
December 13, 2022
San Diego, California--(Newsfile Corp. - December 13, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Topics
Derivatives
Intellectual Property
Exposures
Derivatives
Intellectual Property
Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference
November 22, 2022
San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA
November 17, 2022
San Diego, California--(Newsfile Corp. - November 17, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Topics
Derivatives
Exposures
Derivatives
Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for SBI-100
November 16, 2022
- Recruitment for cohort 1 has begun- ...
Via
Newsfile
Skye Bioscience Closes Acquisition of Emerald Health Therapeutics
November 10, 2022
San Diego, California--(Newsfile Corp. - November 10, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Topics
Cannabis
Exposures
Cannabis
Product Safety
Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.
September 30, 2022
San Diego, California--(Newsfile Corp. - September 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Topics
Derivatives
Exposures
Derivatives
Emerald Health Therapeutics Receives Court Approval of Plan of Arrangement with Skye Bioscience
August 26, 2022
Vancouver, British Columbia--(Newsfile Corp. - August 26, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company")...
Via
Newsfile
Emerald Health Therapeutics Shareholders Vote in Favour of Plan of Arrangement with Skye Bioscience
August 19, 2022
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the...
Via
Newsfile
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion
June 30, 2022
San Diego, California--(Newsfile Corp. - June 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical...
Via
Newsfile
Emerald Health Therapeutics Signs Arrangement Agreement with Skye Bioscience
May 12, 2022
Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to...
Via
Newsfile
Topics
Derivatives
Exposures
Derivatives
CEO Presenting on the Emerging Growth Conference on June 9. Register here
June 07, 2021
Niche Companies in Technology, Biotech, Precious Metals, and more in Attendance
Via
EIN Presswire
Keynotes, Educational Panels and 66 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on April 20-22, 2021
April 19, 2021
LOS ANGELES, CA / ACCESSWIRE / April 19, 2021 / The Planet MicroCap Showcase will take place on April 20-22, 2021, where 66 SmallCap, MicroCap and NanoCap public and private companies will be...
From
Stock News Now
Via
AccessWire
Topics
Cannabis
Exposures
Cannabis
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.